Wall Street analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to post $1.48 billion in sales for the current fiscal quarter, according to Zacks. Eight analysts have made estimates for Regeneron Pharmaceuticals’ earnings. The highest sales estimate is $1.53 billion and the lowest is $1.41 billion. Regeneron Pharmaceuticals posted sales of $1.23 billion in the same quarter last year, which would indicate a positive year-over-year growth rate of 20.3%. The business is expected to report its next quarterly earnings results on Thursday, February 8th.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year sales of $1.48 billion for the current financial year, with estimates ranging from $5.69 billion to $5.81 billion. For the next year, analysts anticipate that the company will post sales of $6.26 billion per share, with estimates ranging from $5.89 billion to $6.76 billion. Zacks Investment Research’s sales calculations are a mean average based on a survey of research analysts that that provide coverage for Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Wednesday, November 8th. The biopharmaceutical company reported $3.99 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.83 by $0.16. The company had revenue of $1.50 billion for the quarter, compared to the consensus estimate of $1.45 billion. Regeneron Pharmaceuticals had a return on equity of 25.73% and a net margin of 23.17%. Regeneron Pharmaceuticals’s quarterly revenue was up 23.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $3.13 EPS.
Several equities analysts have commented on the company. BTIG Research reaffirmed a “buy” rating and issued a $520.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Wednesday, November 22nd. BMO Capital Markets set a $444.00 price objective on Regeneron Pharmaceuticals and gave the company a “hold” rating in a research report on Monday, November 27th. Credit Suisse Group reaffirmed a “buy” rating and issued a $485.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Monday, September 11th. Citigroup cut Regeneron Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $480.00 to $380.00 in a report on Friday, December 1st. Finally, Piper Jaffray Companies reiterated a “buy” rating and issued a $540.00 target price on shares of Regeneron Pharmaceuticals in a report on Monday, November 13th. Two investment analysts have rated the stock with a sell rating, seventeen have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Hold” and a consensus target price of $466.14.
In related news, Director Michael S. Brown sold 1,500 shares of the company’s stock in a transaction on Thursday, October 5th. The stock was sold at an average price of $475.00, for a total transaction of $712,500.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 10.80% of the company’s stock.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Fieldpoint Private Securities LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $130,000. Sterling Investment Advisors Ltd. lifted its stake in shares of Regeneron Pharmaceuticals by 11.2% during the 2nd quarter. Sterling Investment Advisors Ltd. now owns 278 shares of the biopharmaceutical company’s stock worth $137,000 after purchasing an additional 28 shares during the last quarter. FNY Partners Fund LP lifted its stake in shares of Regeneron Pharmaceuticals by 200.0% during the 2nd quarter. FNY Partners Fund LP now owns 300 shares of the biopharmaceutical company’s stock worth $147,000 after purchasing an additional 200 shares during the last quarter. Virtu KCG Holdings LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth $206,000. Finally, Vident Investment Advisory LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the 3rd quarter worth $200,000. Hedge funds and other institutional investors own 66.63% of the company’s stock.
Shares of Regeneron Pharmaceuticals (REGN) traded down $6.86 during trading on Friday, reaching $375.96. The company’s stock had a trading volume of 623,976 shares, compared to its average volume of 790,792. The company has a market cap of $40,390.00, a P/E ratio of 34.15, a PEG ratio of 1.50 and a beta of 1.53. The company has a quick ratio of 3.07, a current ratio of 3.63 and a debt-to-equity ratio of 0.12. Regeneron Pharmaceuticals has a 12 month low of $340.09 and a 12 month high of $543.55.
TRADEMARK VIOLATION NOTICE: “Regeneron Pharmaceuticals Inc (REGN) Expected to Announce Quarterly Sales of $1.48 Billion” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dispatchtribunal.com/2018/01/14/regeneron-pharmaceuticals-inc-regn-expected-to-announce-quarterly-sales-of-1-48-billion.html.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Get a free copy of the Zacks research report on Regeneron Pharmaceuticals (REGN)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.